Consensus Bausch + Lomb Corporation

Equities

BLCO

CA0717051076

Market Closed - Nyse Other stock markets 04:00:02 2024-05-06 pm EDT			5-day change	1st Jan Change
14.44 ^USD	+6.18%		-4.50%	-15.36%

May. 06	Bausch + Lomb Shares Rise After Morgan Stanley Upgrade	MT
May. 06	Morgan Stanley Upgrades Bausch + Lomb to Overweight From Equalweight, Raises Price Target to $18 From $16	MT

Evolution of the average Target Price on Bausch + Lomb Corporation

Price target over the last 5 years

History of analyst recommendation changes

b9a3f5fe38f555711cfa1de0bce9.OxSR7CzE4A3jZJfoNHC0JpfbZ88r-6D7Hd2Z9yIgUjs.CCTCh1WmpEaRMvGYUUXiQ9WWKpBSkpiyZ4eshnURNF0CTt_ZFL2XZNoD9A~ee6a4ef69886eb2a758f9b07eddc55ce

Analyst Recommendations on Bausch + Lomb Corporation

Bausch + Lomb Shares Rise After Morgan Stanley Upgrade	May. 06	MT
Morgan Stanley Upgrades Bausch + Lomb to Overweight From Equalweight, Raises Price Target to $18 From $16	May. 06	MT
Deutsche Bank Adjusts Bausch + Lomb Price Target to $14 From $18, Maintains Hold Rating	May. 02	MT
RBC Cuts Price Target on Bausch + Lomb to $18 From $20, Keeps Outperform Rating	Apr. 22	MT
RBC Ups PT on Bausch Health Companies to $12 From $9 Reflecting Upcoming Appellate Court Decisions & Potential BLCO Distribution, Maintains Sector Perform Rating	Apr. 05	MT
Barclays Raises Price Target on Bausch + Lomb to $18 From $17, Maintains Equalweight Rating	Feb. 26	MT
Wells Fargo Ups Price Target on Bausch + Lomb to $23 From $21, Maintains Overweight Rating	Feb. 22	MT
RBC Lifts Price Target on Bausch + Lomb to $20 From $19 After Better-Than-Expected Q4, Above-Consensus 2024 Revenue Guidance; Outperform Kept	Feb. 22	MT
RBC Trims Price Target on Bausch + Lomb to $19 From $20 Ahead of Q4 2023 Report, Keeps Outperform Rating	Feb. 09	MT
Evercore ISI Downgrades Bausch + Lomb to In Line From Outperform, Adjusts Price Target to $17 From $19	Jan. 04	MT
Stifel Initiates Bausch + Lomb With Hold Rating, $16 Price Target	Dec. 12	MT
Morgan Stanley Trims Price Target on Bausch + Lomb to $16 From $17, Maintains Equal-Weight Rating	Dec. 04	MT
RBC Trims Price Target on Bausch + Lomb to $20 From $21 Amid Foreign-Exchange Headwinds, Keeps Outperform Rating	23-10-23	MT
Morgan Stanley Adjusts Price Target on Bausch + Lomb to $18.50 From $20, Keeps Equalweight Rating	23-10-13	MT
Fitch Affirms Bausch Health, Bausch Health America's Ratings; Bausch + Lomb's Rating Maintained	23-10-04	MT
Moody's Rates Bausch + Lomb's New Secured Debt Instruments	23-09-12	MT
Fitch Assigns Rating to Bausch + Lomb's Secured Term Loan, Secured Bond; Up 1.4%	23-09-11	MT
Barclays Adjusts Price Target on Bausch + Lomb to $19 From $18, Maintains Equalweight Rating	23-08-03	MT
Needham & Co Maintains Hold Rating on Bausch + Lomb After Q2	23-08-02	MT
Toronto Stocks Drop Amid U.S. Credit-Rating Downgrade; Cameco Shares Down	23-08-02	DJ
TSX futures decline after Fitch downgrades US credit rating	23-08-02	RE
RBC Lifts Price Target on Bausch + Lomb to $21 From $20 Ahead of Q2 Report, Maintains Outperform Rating	23-07-24	MT
BofA Securities Raises Price Target on Bausch + Lomb to $23 From $19, Maintains Buy Rating	23-07-03	MT
Needham & Co "Incrementally More Positive" on Bausch + Lomb After Xiidra Announcement, But Maintains Hold Rating	23-06-30	MT
HC Wainwright Adjusts Price Target on Bausch + Lomb to $22 From $19, Keeps Buy Rating	23-05-19	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

14.44 USD

Average target price

18.71 USD

Spread / Average Target

+29.60%

High Price Target

25 USD

Spread / Highest target

+73.13%

Low Price Target

14 USD

Spread / Lowest Target

-3.05%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Bausch + Lomb Corporation

Deutsche Bank Securities
RBC Capital Markets
Barclays
Wells Fargo Securities
Evercore ISI
Stifel Nicolaus
Morgan Stanley
BofA Securities
HC Wainwright
Needham & Co.
Goldman Sachs
Citigroup
Jefferies & Co.
Guggenheim
JPMorgan Chase
Cowen

Ratings for Bausch + Lomb Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar